We recently published 10 Stocks Leaving Wall Street in the Dust; 4 Hit Fresh Records. Moderna Inc. (NASDAQ:MRNA) was one of ...

Moderna (MRNA) has jumped back into focus after its JPMorgan Healthcare Conference update, where management lifted the 2025 ...

MRNA shares rise after upbeat 2025 sales, stronger cash outlook and detailed 2026 guidance, alongside multiple pipeline ...

Moderna Inc.’s chairman says the Trump administration’s vaccine policy changes are part of a broader attack on science that ...

Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...

Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 ...

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

Moderna is up 20% YTD, with a golden cross suggesting a trend reversal. Momentum indicators make it a top 2026 pick.

Moderna said on Monday it expects to report around $1.9  billion in sales for 2025, putting it near the upper end of its ...

SAN FRANCISCO — Despite all the hopeful chatter about the life sciences industry making a rebound after a multiyear ...

Moderna CEO Stéphane Bancel positions 2026 as a catalyst-rich year driven by new vaccine launches, late-stage oncology data, ...

Moderna shares are volatile Monday after the company provided updates on its business and pipeline at a healthcare conference ...